EXoZymes Raises April Fundraising to Back NCT and Cannabinoid Scale-Up
EXoZymes is fundraising in April to finance its pre-revenue operations, building biomanufacturing assets and AI-assisted enzyme engineering to commercialize its NCT and cannabinoid platforms. The company holds liquidity into Q2 2026 yet incurred a net loss from higher R&D investments and personnel expansion.
1. April Fundraising and Cash Runway
EXoZymes plans to start fundraising in April to secure funding through Q2 2026, aiming to finance ongoing operations and scale-up efforts towards operating break-even.
2. Biomanufacturing Platform and AI Tools
The company is building core biomanufacturing assets and leveraging AI-assisted enzyme engineering to develop tech-transfer packages, aiming for competitive advantage in high-value molecule production.
3. NCT and Cannabinoid Program Advances
Progress on the NCT product includes high-purity, scalable outputs with Cayman Chemicals partnership sequencing process optimization and readiness for commercial production; provisional patents have been filed for new cannabinoid analogs.
4. Financial Performance and Outlook
EXoZymes reported a net loss for FY 2025 driven by increased R&D and personnel costs, maintaining sufficient liquidity while exploring non-dilutive funding and joint venture opportunities.